Immunoaffinity Targeted Mass Spectrometry Analysis of Human Plasma Samples Reveals an Imbalance of Active and Inactive CXCL10 in Primary Sjögren's Syndrome Disease Patients.

CXCL10 DPP4 N-terminal degradation parallel reaction monitoring primary Sjögren’s Syndrome proteoform quantification stable isotope dilution targeted mass spectrometry

Journal

Journal of proteome research
ISSN: 1535-3907
Titre abrégé: J Proteome Res
Pays: United States
ID NLM: 101128775

Informations de publication

Date de publication:
02 10 2020
Historique:
pubmed: 2 9 2020
medline: 22 6 2021
entrez: 2 9 2020
Statut: ppublish

Résumé

One of the most important advantages of mass spectrometry is the ability to quantify proteins and their modifications in parallel to obtain a holistic picture of the protein of interest. Here, we present a hybrid immunoaffinity targeted mass spectrometry (MS) method that combines efficient pan-antibody enrichment of a specific protein from plasma with the selectivity of high-resolution targeted MS analysis to quantitate specific proteoforms of interest. We used this approach to quantify plasma levels of the chemokine CXCL10 that has been associated with many immunological disorders such as systemic lupus erythematosus and primary Sjögren's Syndrome (pSS). The hybrid approach enabled sensitive, specific, and simultaneous quantification of total, full-length (active) CXCL10

Identifiants

pubmed: 32870689
doi: 10.1021/acs.jproteome.0c00494
doi:

Substances chimiques

Biomarkers 0
CXCL10 protein, human 0
Chemokine CXCL10 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4196-4209

Auteurs

Alexander Schmidt (A)

Biozentrum, University of Basel, Klingelbergstrasse 50/70, CH-4056 Basel, Switzerland.

Hervé Farine (H)

Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland.

Marcel P Keller (MP)

Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland.

Agata Sebastian (A)

Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Borowska 210, 50-556 Wroclaw, Poland.

Lukasz Kozera (L)

Lukasiewicz Research Network - PORT Polish Center for Technology Development, National Biobanking Node, Stablowicka 147, 50-066 Wroclaw, Poland.

Richard W D Welford (RWD)

Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland.

Daniel S Strasser (DS)

Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH